Aminoglutethimide
From Wikipedia, the free encyclopedia
Aminoglutethimide
|
|
Systematic (IUPAC) name | |
3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione | |
Identifiers | |
CAS number | |
ATC code | L02 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C13H16N2O2 |
Mol. mass | 232.278 g/mol |
Pharmacokinetic data | |
Bioavailability | >95% |
Metabolism | Hepatic |
Half life | 12.5 ± 1.6 hours |
Excretion | Renal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status | |
Routes | Oral |
Aminoglutethimide blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme desmolase, thus inhibits synthesis of all hormonally active steroids. It can be used in conjunction with other drugs for treatment of steroid-producing adrenocortical cancer.
Its major side effects are liver toxicity, inhibition of cortisol in the human body, and it may also cause hypothyroidism. Since cortisol helps break down muscle, aminoglutethimide is used by bodybuilders in a steroid cycle.
It is still used to suppress corticosteroid production in Cushing's Syndrome.
It is marketed under the tradename Cytadren.
[edit] Clinical uses
Aminoglutethimide is indicated for the suppression of adrenal function in selected patients with Cushing's syndrome.
[edit] External links
- Cytadren prescribing information (from the FDA website)
- Medline Plus